Researchers at Circulate Health and the Buck Institute for Research on Aging have made a groundbreaking discovery, finding that therapeutic plasma exchange (TPE) combined with intravenous immunoglobulin (IVIG) significantly reduces biological age by an average of 2.61 years. This trial is believed to be the first comprehensive study to assess the rejuvenative potential of TPE using molecular profiling.
The study involved 42 participants aged over 50 and explored how different TPE regimens affected biological aging markers across various domains, including epigenetics, proteomics, and immunology. The results showed that TPE led to measurable reductions in biological age across all treatment groups, with the most significant effects seen in those receiving both TPE and IVIG.
Participants who experienced poorer baseline health saw the greatest benefits, while even healthier individuals saw improvements in physical performance. The researchers also found that combining TPE with IVIG added value, restoring immune cell profiles typically altered with age and modulating proteins associated with cellular senescence.
While limitations exist, including small cohort sizes, the study’s findings are promising. Kaeberlein, CEO of Optispan, is optimistic about TPE’s potential, particularly in areas like chronic inflammation and neurodegeneration. He plans to undergo his first round of therapeutic plasma exchange soon and expects to see positive results.
TPE, a process that involves circulating a patient’s blood through an apheresis machine to eliminate disease-promoting substances, has been well-established in treating autoimmune and neurological disorders. The study’s findings suggest its potential applications in aging and longevity science are promising.
Source: https://longevity.technology/news/human-trial-finds-therapeutic-plasma-exchange-reduces-biological-age